# Aveanna Healthcare Holdings Inc. (AVAH)

> Source: Nexqual · https://nexqual.com/AVAH · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, Aveanna Healthcare Holdings Inc. (AVAH), nexqual.com/AVAH" · informational, not investment advice.

**Price:** USD 13.32 (+2.54% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 12.99 · day 13.03–13.34 · 52w 5.93–14.71 · market cap $2.91B · NMS

## Key facts
- Last four reported quarters (through Jul 4, 2026): revenue $2.60B, net income $275M (10.6% margin) (SEC filings).
- Valuation: P/E 10.6x (avg 8.0x at the last 1 fiscal year-ends), EV/EBITDA 14.4x, net debt $1.20B.
- 1 of 80 tracked superinvestors hold AVAH (13F, Q2 2026): 0 new, 0 added, 1 reduced, 0 unchanged.
- Insider open-market sales, last ~7 months: 16 Form 4 filings, $774M; 16 not under a Rule 10b5-1 plan ($774M); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 2.09 on a 1–5 scale) (11 analysts), mean target USD 14.85 (range 13–16).
- Total return with dividends: 1Y +46.0% vs S&P 500 +14.9%; 5Y +84.5% vs S&P 500 +80.3%.
- Next earnings: 2026-11-12, EPS estimate USD 0.21, revenue estimate $681M.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $1.68B | $1.79B | $1.90B | $2.02B | $2.43B | $2.60B |
| Gross profit | $542M | $553M | $595M | $636M | $810M | — |
| Operating income | -$36.1M | -$642M | $8.1M | $140M | $256M | $274M |
| Net income | -$117M | -$662M | -$135M | -$10.9M | $225M | $275M |
| EPS (diluted) | -$0.69 | -$3.57 | -$0.71 | -$0.06 | $1.05 | — |
| Free cash flow | -$27.3M | — | — | — | — | — |
| Gross margin | 32.3% | 30.9% | 31.4% | 31.4% | 33.3% | — |
| Operating margin | -2.2% | -35.9% | 0.4% | 6.9% | 10.5% | 10.5% |
| Net margin | -7.0% | -37.0% | -7.1% | -0.5% | 9.2% | 10.6% |
| Revenue growth | +12.3% | +6.5% | +6.0% | +6.8% | +20.2% | — |
| Cash + short-term investments | $30.5M | $19.2M | $43.9M | $84.3M | $193M | — |
| Total debt | $1.24B | $1.29B | $1.29B | $1.28B | $1.30B | — |
Fiscal years end Jan. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jul 4, 2026)
P/E 10.6x · P/S 1.1x · EV/EBITDA 14.4x · EV/Sales 1.6x · P/B 10.1x · Earnings yield 9.45% · Net debt $1.20B · EV $4.11B
P/E at fiscal year-ends: Jan 2026 8.0x.

## Superinvestors (SEC 13F-HR, Q2 2026)
1 of 80 tracked investors hold AVAH. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| First Eagle Investment | First Eagle Investment Management | 0.01% | $6.6M | Reduced -0.3% |

## Insider sales (SEC Form 4, open-market, last ~7 months)
0 of 16 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-08-20…2026-08-21 | J.H. Whitney Equity Partners Vii, Llc |  | 14,746,077 | $170M | 54.5% | No | Too little history (no open-market trades in 2023 or 2024) |
| 2026-08-20…2026-08-21 | Williams Robert M Jr |  | 16,750,002 | $193M | 57.6% | No | Too little history (no open-market trades in 2023 or 2024) |
| 2026-08-20…2026-08-21 | Vigano Paul R |  | 16,750,002 | $193M | 57.6% | No | Too little history (no open-market trades in 2023 or 2024) |
| 2026-08-20 | Windley Rodney D | Director | 180,000 | $2.1M | 8% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-08-20 | Shaner Jeff | Chief Executive Officer | 90,000 | $1.0M | 3.4% | No | Too little history (no open-market trades in 2023 or 2024) |
| 2026-08-20 | Reisz Edwin C. | Chief Administrative Officer | 50,000 | $575K | 3.5% | No | Too little history (no open-market trades in 2023 or 2024) |
| 2026-06-30 | Williams Robert M Jr |  | 3,000,000 | $24.0M | 9.4% | No | Too little history (no open-market trades in 2023 or 2024) |
| 2026-06-30 | Vigano Paul R |  | 3,000,000 | $24.0M | 9.4% | No | Too little history (no open-market trades in 2023 or 2024) |
| 2026-06-30 | J.H. Whitney Equity Partners Vii, Llc |  | 2,419,035 | $19.4M | 8.2% | No | Too little history (no open-market trades in 2023 or 2024) |
| 2026-06-24 | Williams Robert M Jr |  | 1,000,000 | $8.0M | 3% | No | Too little history (no open-market trades in 2023 or 2024) |
| 2026-06-24 | J.H. Whitney Equity Partners Vii, Llc |  | 919,389 | $7.4M | 3% | No | Too little history (no open-market trades in 2023 or 2024) |
| 2026-06-24 | Vigano Paul R |  | 1,000,000 | $8.0M | 3% | No | Too little history (no open-market trades in 2023 or 2024) |
| 2026-06-03 | Vigano Paul R |  | 7,000,000 | $43.7M | 17.5% | No | Too little history (no open-market trades in 2023 or 2024) |
| 2026-06-03 | Williams Robert M Jr |  | 7,000,000 | $43.7M | 17.5% | No | Too little history (no open-market trades in 2023 or 2024) |
| 2026-06-03 | J.H. Whitney Equity Partners Vii, Llc |  | 5,842,240 | $36.5M | 16.1% | No | Too little history (no open-market trades in 2023 or 2024) |
| 2026-05-20 | Cunningham Patrick A. | Chief Compliance Officer | 125,000 | $949K | 37% | No | Too little history (no open-market trades in 2023 or 2024) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Consensus Buy (mean 2.09 on a 1–5 scale), 11 analysts; mean target USD 14.85 (low 13, high 16).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-14 | JP Morgan | Target raised | Neutral | $8 → $15 |
| 2026-08-28 | Barclays | Target raised | Overweight | $9.5 → $15 |
| 2026-08-24 | Truist Securities | Target raised | Hold | $11 → $15 |
| 2026-08-24 | RBC Capital | Target raised | Outperform | $10 → $16 |
| 2026-08-14 | UBS | Target raised | Neutral | $8 → $13 |
| 2026-08-14 | Raymond James | Target raised | Strong Buy | $13 → $15 |
| 2026-08-14 | BMO Capital | Target raised | Outperform | $10 → $14 |
| 2026-07-14 | Truist Securities | Target raised | Hold | $9 → $11 |
| 2026-07-09 | Barclays | Target raised | Overweight | $9 → $9.5 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | +46.0% | +84.5% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +46.2% | +13.0% |
| Volatility (annualized) | 47.6% | 75.5% |
| Max drawdown | -36.9% (Oct 2025→Apr 2026) | -91.3% (Nov 2021→Nov 2022) |

## Peers (Medical Care Facilities)
ACHC (Acadia Healthcare Company, Inc.) USD 31.88 +1.43% · GRDN (Guardian Pharmacy Services, Inc) USD 39.59 +1.56% · BKD (Brookdale Senior Living Inc.) USD 10.19 +1.09% · MD (Pediatrix Medical Group, Inc.) USD 29.55 +5.16% · ADUS (Addus HomeCare Corporation) USD 122.67 +4.00% · NHC (National HealthCare Corporation) USD 243.07 +3.17%

## More
Full page: https://nexqual.com/AVAH · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Revenue by business segment (quarter ended 2026-07-04)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| Private Duty Services | $553.9M | 82.6% | +14.0% |
| Home Health & Hospice | $69.0M | 10.3% | +14.8% |
| Medical Solutions | $47.5M | 7.1% | +9.4% |
| Total revenue | $670.5M | 100% | — |

## Customer concentration

Period ended 2026-07-04: 59.4%, 21.1%, 10%, 9.3%, 0.2% of revenue from unnamed direct customers (10-Q, filed 2026-08-13).

## Company outlook (8-K filed 2026-08-13)

- "The following is our guidance reflecting our increased expectations for revenue and Adjusted EBITDA for the full fiscal year 2026 (year ending January 2, 2027): • Revenue of greater than $2.68 billion, updated from between $2.63 and $2.65 billion."
- "Consistent with prior practice, we are not providing guidance on net income at this time due to the volatility of certain required inputs that are not available without unreasonable efforts, including future fair value adjustments associated with our interest rate caps. • Adjusted EBITDA of greater than $365 million, updated from between $338 and $342 million."

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $0.21 | $0.17 | +20.3% | $680.6M | 10 |
| Next quarter (ends 2026-12-31) | $0.21 | $0.18 | +17.2% | $694.9M | 10 |
| Current fiscal year (ends 2026-12-31) | $0.82 | $0.71 | +16.8% | $2.69B | 11 |
| Next fiscal year (ends 2027-12-31) | $0.91 | $0.77 | +17.2% | $2.90B | 11 |